Literature DB >> 22813482

Group B streptococcal colonization and the risk of pre-eclampsia.

Z D Mulla1, V Annavajjhala, J L Gonzalez-Sanchez, M R Simon, B S Nuwayhid.   

Abstract

To determine if there was an association between recto-vaginal group B streptococcus (GBS) colonization and pre-eclampsia, two cross-sectional studies were conducted using statewide hospital databases. The first study analysed data from the state of Florida, USA, and included 190 645 women who were discharged in 2001. This dataset was used to generate the hypothesis that GBS colonization is associated with pre-eclampsia. The second study tested the GBS hypothesis using the records of 577 153 women who delivered in 2004 or 2005 in Texas, USA. Adjusted odds ratios (aOR) for the outcome of pre-eclampsia comparing GBS-positive to GBS-negative women were calculated using logistic regression. The aOR for the association between GBS carriage and pre-eclampsia was 0.71 [95% confidence interval (CI) 0.65-0.77] in the Florida dataset. In the Texas dataset, the overall prevalence of GBS carriage was 14.1% while the overall prevalence of pre-eclampsia was 4.0%. GBS carriers were 31% less likely than non-carriers to have pre-eclampsia (aOR 0.69, 95% CI 0.66-0.72) in Texas. In two large statewide analyses, GBS carriage was inversely associated with pre-eclampsia. A sensitivity analysis revealed that misclassification of GBS status is not a likely explanation of our findings.

Entities:  

Mesh:

Year:  2012        PMID: 22813482      PMCID: PMC9151833          DOI: 10.1017/S0950268812001598

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  32 in total

1.  Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births.

Authors:  Dorothea Mostello; Dorina Kallogjeri; Rachata Tungsiripat; Terry Leet
Journal:  Am J Obstet Gynecol       Date:  2008-02-15       Impact factor: 8.661

2.  Bioactive tumour necrosis factor alpha in pre-eclamptic patients with and without the HELLP syndrome.

Authors:  W Visser; I Beckmann; H A Bremer; H L Lim; H C Wallenburg
Journal:  Br J Obstet Gynaecol       Date:  1994-12

3.  Recurrent versus isolated pre-eclampsia and risk of feto-infant morbidity outcomes: racial/ethnic disparity.

Authors:  Alfred K Mbah; Amina P Alio; Phillip J Marty; Karen Bruder; R Wilson; Hamisu M Salihu
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2011-02-11       Impact factor: 2.435

4.  Is infection a major risk factor for preeclampsia?

Authors:  J A Herrera; G Chaudhuri; P López-Jaramillo
Journal:  Med Hypotheses       Date:  2001-09       Impact factor: 1.538

5.  Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci.

Authors:  D J Kwak; N H Augustine; W G Borges; J L Joyner; W F Green; H R Hill
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

6.  Descriptive and clinical epidemiology of preeclampsia and eclampsia in Florida.

Authors:  Zuber D Mulla; José L Gonzalez-Sanchez; Bahij S Nuwayhid
Journal:  Ethn Dis       Date:  2007       Impact factor: 1.847

7.  Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia.

Authors:  G Chen; S H Wang; H Z Zheng; J J Walker; J H McKillop
Journal:  Clin Exp Immunol       Date:  1996-04       Impact factor: 4.330

8.  Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1.

Authors:  D Wallach; H Holtmann; H Engelmann; Y Nophar
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

9.  The risk of preeclampsia rises with increasing prepregnancy body mass index.

Authors:  Lisa M Bodnar; Roberta B Ness; Nina Markovic; James M Roberts
Journal:  Ann Epidemiol       Date:  2005-08       Impact factor: 3.797

10.  Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1.

Authors:  K Karmann; W Min; W C Fanslow; J S Pober
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.